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treatment”). Cost per STP in 2001 is lower for tolterodine
(5523L. (€2.85)) than oxybutynin (17265L. (€8.92)). The
“no treatment” group demonstrated the highest non-drug
costs while providing no efficacy.
CONCLUSION: This economic model demonstrates that
tolterodine is more cost-effective than oxybutynin in
treating unstable bladder as measured by cost per suc-
cessfully treated patient in Italy.
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OBJECTIVES: Urinary incontinence and overactive blad-
der disorders are not recognized as significant issues for
employed populations. Perceived as a problem for women
over 50, and frequently undiagnosed, these conditions
may have undetected effects on employee health costs and
productivity. Using a large, longitudinal, multi-employer
health-care database this investigation examined inci-
dence and benefit use by employees who had a diagnosis
of urinary incontinence or overactive bladder disorder
(OAB).
METHODS: OAB was defined by ICD9 codes 595, 596
and 788. Incidence was estimated from a medical claims
database of 230,000 employees. Excess benefit costs were
derived from a subset (n  36,777) with four-years of
medical, absence, disability, and workers-compensation
(WC) data. Using a censored regression model to control
for differences in demographics, job and health charac-
teristics expected incremental-benefit costs for OAB were
calculated.
RESULTS: 2.58% of employees had OAB. Employees
with OAB were significantly (p  .01) older and more
likely to be female. Employees with OAB had significantly
(p  .001) higher costs for all benefits except WC (*p 
.19) and had a greater likelihood of filing disability claims.
Controlling other factors, OAB employees had higher
costs for medical (diff  $995), sick leave (diff  $151),
STD (diff  $148), LTD (diff  $76), and *WC (diff 
$178). Total difference was $1,548 per OAB employee.
Where individual productivity data were available, em-
ployees with OAB produced 5% fewer units annually, al-
though this is not statistically significant (p  .34).
CONCULSIONS: OAB was detected in one in every 40
employees. Employees with OAB were higher users of
health-related benefits, more costly overall, and absent
more frequently. As such, OAB may be a hidden source
of health costs for employers. More research needs to be
done to determine what portion of OAB-associated costs
can be avoided through appropriate treatment.
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OBJECTIVE: The aim of this study was to compare the
costs, efficacy and safety of basiliximab (Simulect) versus
Thymoglobuline in the treatment of renal transplant in-
duction.
METHODS: We carried out an economic evaluation
based on the data from clinical trial CHI-F-02. A total of
100 patients, fifty in each group, were recruited from
nine sites across France. We estimated the direct medical
costs of two strategies of renal transplant induction ther-
apy incurred over six months in a piggy-back approach.
Direct medical costs covered medications, hospital stays,
dialysis, consultations and examinations not scheduled
by the protocol. As both treatments offer the same effi-
cacy, we ran a cost-minimisation study. The cost of care
was analysed from a hospital perspective. Wilcoxon rank
sum tests were performed to analyse the cost differences
between the two strategies.
RESULTS: The study showed a significant reduction in
the duration of initial hospital stay in the Simulect arm,
as well as a significant reduction in the number of infec-
tious episodes. Therefore, although the average cost of
treatment with Simulect appears slightly higher than the
cost with Thymoglobuline (2964 versus 2298 Euros), the
cost of initial hospitalization is significantly lower in the
Simulect arm (10 900 versus 11 967 Euros, p  0.02).
Furthermore the mean cost of infectious episodes is sig-
nificantly lower in the Simulect arm (1056 versus 1790
Euros, p  .03). CMV infection accounts for 30% of this
cost in the Simulect arm and 53% in the Thymoglobuline
arm with a significantly different cost (p  0.01).
CONCLUSION: In terms of direct medical costs, this
study shows a saving of 1067 Euros per patient in the
Simulect arm, which compensates for the initial higher
price of this immunosuppressive drug.
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